Evidence map›Paper›PMID 33008332›Full record

ArticleBMC cancer2020

Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel.

Hakon Blomstrand, Henrik Green, Mats Fredrikson, Emma Gränsmark, Bergthor Björnsson, Nils O Elander

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Observational
  4. Article
  5. Review
  6. Article
  7. Article
  8. The efficacy and safety of gemcitabine-based combination therapyJournal of gastrointestinal oncology · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Hakon BlomstrandDepartment of Clinical Pathology and Department of Biomedical and Clinical Sciences, Linköping University, 58183, Linköping, Sweden.
Henrik GreenDivision of Drug Research, Department of Medical Health Sciences, Linköping University, 58183, Linköping, Sweden.
Mats FredriksonForum Östergötland, Linköping University, 58185, Linköping, Sweden.
Emma GränsmarkDepartment of Oncology, Kalmar County Hospital, 392 44, Kalmar, Sweden.
Bergthor BjörnssonDepartment of Surgery and Department of Biomedical and Clinical Sciences, Linköping University, 58183, Linköping, Sweden.
Nils O ElanderDepartment of Oncology and Department of Biomedical and Clinical Sciences, Linköping University, 58183, Linköping, Sweden. nils.elander@liu.se.
Linköping University · SELandstinget i Kalmar län · SE

Funding

ALF Region Östergotland LIO-697991, LIO- 707011, and LIO-697461CKOC Region Östergötland -Futurum, Academy for Health and Care Jönköping County Council 695491Medical Research Council of Southeast Sweden FORSS-751541Sveriges Gastro-Onkologiska Förening (GOF) -Swedish Cancer Society -
6 · The paper itself

Abstract

backgroundIn recent years treatment options for advanced pancreatic cancer have markedly improved, and a combination regimen of gemcitabine and nab-paclitaxel is now considered standard of care in Sweden and elsewhere. Nevertheless, a majority of patients do not respond to treatment. In order to guide the individual patient to the most beneficial therapeutic strategy, simple and easily available prognostic and predictive markers are needed.

methodsThe potential prognostic value of a range of blood/serum parameters, patient-, and tumour characteristics was explored in a retrospective cohort of 75 patients treated with gemcitabine/nab-paclitaxel (Gem/NabP) for advanced pancreatic ductal adenocarcinoma (PDAC) in the South Eastern Region of Sweden. Primary outcome was overall survival (OS) while progression free survival (PFS) was the key secondary outcome.

resultUnivariable Cox regression analysis revealed that high baseline serum albumin (> 37 g/L) and older age (> 65) were positive prognostic markers for OS, and in multivariable regression analysis both parameters were confirmed to be independent prognostic variables (HR 0.48, p = 0.023 and HR = 0.47, p = 0.039,). Thrombocytopenia at any time during the treatment was an independent predictor for improved progression free survival (PFS) but not for OS (HR 0.49, p = 0.029, 0.54, p = 0.073), whereas thrombocytopenia developed under cycle 1 was neither related with OS nor PFS (HR 0.87, p = 0.384, HR 1.04, p = 0.771). Other parameters assessed (gender, tumour stage, ECOG performance status, myelosuppression, baseline serum CA19-9, and baseline serum bilirubin levels) were not significantly associated with survival.

conclusionSerum albumin at baseline is a prognostic factor with palliative Gem/NabP in advanced PDAC, and should be further assessed as a tool for risk stratification. Older age was associated with improved survival, which encourages further studies on the use of Gem/NabP in the elderly.

Indexed as

AgedAlbuminsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorDeoxycytidineFemaleGemcitabineHumansMalePaclitaxelPancreatic NeoplasmsPrognosisTreatment Outcome130-nm albumin-bound paclitaxelAlbuminsBiomarkers, TumorDeoxycytidineGemcitabinePaclitaxelGemcitabineNab-paclitaxelPancreatic cancerPrognostic markersSerum albumin

Identifiers

PMID33008332
PMCPMC7530950
OpenAlexW3091392689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.